Core D: Biospecimen

$391,665U19FY2017AGNIH

Johns Hopkins University, Baltimore MD

Investigators

Linked publications & trials

Paper 39574713 Paper 39528671 Paper 39484387 Paper 39310214 Paper 39220624 Paper 39147830 Paper 39129354 Paper 39118132 Paper 39102080 Paper 38977137 Paper 38823249 Paper 38664422 Paper 38496536 Paper 38344221 Paper 38327094 Paper 38264712 Paper 38204173 Paper 38191573 Paper 38109776 Paper 38089920 Paper 38036915 Paper 38014176 Paper 37986731 Paper 37849657 Paper 37745408 Paper 37742656 Paper 37653343 Paper 37595576 Paper 37546928 Paper 37522277 Paper 37509130 Paper 37398476 Paper 37345460 Paper 37293032 Paper 37214955 Paper 37035880 Paper 37034653 Paper 36994162 Paper 36978190 Paper 36934675 Paper 36909631 Paper 36865237 Paper 36752121 Paper 36744337 Paper 36700738 Paper 36415591 Paper 36216518 Paper 36017766 Paper 35925685 Paper 35903538 Paper 35791732 Paper 35756247 Paper 35611306 Paper 35551019 Paper 35468989 Paper 35425899 Paper 35398188 Paper 35218111 Paper 35213370 Paper 34862382 Paper 34686968 Paper 34564904 Paper 34184058 Paper 34125126 Paper 34095836 Paper 33249440 Paper 33231528 Paper 33169416 Paper 32989109 Paper 32973425 Paper 32920988 Paper 32873693 Paper 32729964 Paper 32614981 Paper 32568366 Paper 32424284 Paper 32222300 Paper 32211504 Paper 32182160 Paper 32116503 Paper 31994170 Paper 31935468 Paper 31932050 Paper 31888969 Paper 31880315 Paper 31874745 Paper 31755958 Paper 31555121 Paper 31506247 Paper 31372540 Paper 31319126 Paper 31231205 Paper 31012816 Paper 31001108 Paper 30927606 Paper 30842300 Paper 30627880 Paper 30586384 Paper 30578620 Paper 30528841

Abstract

BIOSPECIMEN CORE - CORE D: ABSTRACT The Biospecimen Core (Core D) is responsible for all aspects of cerebrospinal fluid (CSF) and blood collection, storage, and analysis. The aims of the Biospecimen Core are: The specific aims of Biospecimen Core are: (1) Collect, catalog, and store CSF and blood specimens from participants in the BIOCARD study and from patients in the Johns Hopkins CSF Disorders Center (the latter to be used for exploratory analyses). CSF collection will be reinitiated biannually in the BIOCARD cohort, to add to the existing specimens. (2) Perform AlzBio3 assays for CSF A?1-42, total tau, and ptau-181 and an MSD assay for A?1-42 on all newly collected CSF specimens from BIOCARD participants and from well characterized patients in the Johns Hopkins CSF Disorders Center, and compare the validity of the two assays for A?1-42. (3) Examine the utility of new CSF assays as Alzheimer's disease (AD) biomarkers, using samples from patients in the Johns Hopkins CSF Disorders Center for discovery, and from participants in the BIOCARD cohort for validation. These assays will include: (a) a multiplexed assay for inflammatory markers, (b) a proteomics assay for synaptic markers and (c) a metabolomic assay for small molecules.

View original record on NIH RePORTER →